Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, ...
19 小时
Aptevo Therapeutics: Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as ...
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果